Skip to main content
. Author manuscript; available in PMC: 2022 Mar 30.
Published in final edited form as: Eur Urol. 2020 Jun 10;78(3):371–378. doi: 10.1016/j.eururo.2020.05.018

Table 3 –

Summary of recommendation for follow-up after focal therapy of the prostate

First time Years after treatment
0–1 1–2 2–3 3–4 4–5
PSA 3 mo Every 3 mo Every 6 mo Every 6 mo Every 6 mo Every 6 mo
Imaging 6 mo Once (at 6 mo) Once (12 mo after initial) Every 12 mo or as per institutional active surveillance protocol or triggering factor/clinical suspicion
Biopsy
Systematic 6–12 mo Once (at 6–12 mo) If negative: as per institutional active surveillance protocol or triggering factor/clinical suspicion
MRI guided 6–12 mo Once (at 6–12 mo) If negative: as per institutional active surveillance protocol or triggering factor/clinical suspicion
Assessment of functional outcomes 3–6 mo Once (at 3–6 mo) Assessment until stability/baseline attained

MRI = magnetic resonance imaging; PSA = prostate-specific antigen.